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Abstract Psoriasis vulgaris is a chronic inXammatory
skin disease that is marked by a complex interplay of den-
dritic cells (DCs), T-cells, cytokines, and downstream tran-
scription factors as part of a self-sustaining type 1 cytokine
network. As integral players of the immune system, DCs
represent antigen-presenting cells that are crucial for
eYcient activation of T-cells and B-cells. DCs have also
been linked to distinct chronic inXammatory conditions,
including psoriasis. In the setting of psoriasis therapy,
DC/T cell interactions serve as a potential target for
biologic response modiWers. Here we describe the major
DC subsets as well as the immunologic involvement of
DCs within the context of psoriatic lesions.
Introduction
The clearance of psoriasis using targeted immunotherapies
demonstrates the signiWcant roles of T-cells, dendritic cells
(DCs), and cytokines as part of a type 1 inXammatory net-
work [33]. Central to this model are the upstream activation
of DCs, DC-induced cytokine production (IL-12, IL-23),
and antigen presentation to type 1 T-cells. Subsequently,
stimulated T-cells release tumor necrosis factor-alpha
(TNF-), interferon-gamma (IFN-), and other cytokines
[9, 19]. Collectively, TNF- and IFN- induce a wide vari-
ety of responses including: signal transducer and activator
of transcription 1 (STAT1) stimulation followed by expres-
sion of downstream response genes; activation of nuclear
factor kappa B (NF-B) signaling pathways; leukocyte
migration to inXammatory regions; and vasodilation that
results in the erythema that is characteristic of psoriatic
lesions [11, 33, 34, 42]. It has been postulated that TNF-
and IFN- activate keratinocytes that produce a wide vari-
ety of cytokines, which are capable of eVecting DC matura-
tion [22]. Chemokines, which are produced through a
downstream response to IFN-, TNF-, and possibly other
cytokines, also play a role in recruiting leukocytes to areas
of inXammation [33, 58]. The noted cytokine, chemokine,
and cellular interactions may contribute to the self-perpetu-
ation of the type 1 pathway, which can in turn be correlated
with the chronic nature of psoriasis.
DCs are key players in the immune mechanisms sur-
rounding psoriasis, as well as other disease processes. Ini-
tially described by Steinman and Cohn in 1973, as
identiWed in the lymphoid organs of mice, DCs have been
recognized as antigen presenting cells (APCs) that are cru-
cial for the presentation of molecules to T-cells and B-cells
[64]. DCs are bone marrow-derived, circulate in the blood-
stream in immature forms, and migrate into peripheral tis-
sues. Immature DCs function in antigen detection, uptake
and processing, whereas mature DCs primarily function in
antigen presentation as well as cytokine production. DCs
have been linked to diseases of chronic inXammation
including psoriasis, Sjögren’s syndrome, rheumatoid arthri-
tis, systemic lupus erythematosus (SLE), and multiple scle-
rosis [15]. This paper reviews the role of DCs in the
immunopathogenesis of psoriasis, while illustrating: the
DC types and features of each subset; the immunologic
roles and mechanisms of DC interactions; the roles of DCs
in the formation of chronic psoriasis plaques; and the direc-
tions for future DC-related research and targeted immuno-
logic therapies in the treatment of psoriasis.
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DC subsets
In order to gain a better understanding of the immunologic
roles of DCs, it is Wrst necessary to illustrate the distinct DC
subsets and their deWning features as well as speciWc func-
tions. Widely distributed within the human body, DCs cir-
culate in the bloodstream in immature forms and exist
within the vast majority of peripheral tissues under steady-
state conditions; following stimulation, DCs migrate to
lymphoid organs [6]. DCs are thought to contribute to a
local skin-resident immune network: normal skin under
resting conditions contains a large pool of memory T-cells
(i.e. T-cell numbers within normal skin double the number
of circulating T-cells) and APCs, which can respond to
antigenic stimuli and eVect immunologic responses; it is
also believed that keratinocytes secrete cytokines which
may play a role in recruiting T-cells to normal as well as
inXamed skin; normal skin also contains natural killer (NK)
cells, NK T-cells, and macrophages [9, 14]. Several types
of DC progenitors have been demonstrated in human
peripheral blood: CD14+ and CD16+ monocytes; plasmacy-
toid DCs (pDCs); and Langerhans cell (LC) precursors [15,
27, 54, 60, 65] (Table 1). Blood monocytes are believed to
diVerentiate into either tissue macrophages or myeloid
DCs, which are professional APCs [15, 54]. Within human
monocyte subpopulations, CD14+ monocytes predominate
and CD16+ monocytes are relatively infrequent; these
groups diVer in the expression proWles of chemokine recep-
tors and adhesion molecules [65]. Another DC subset that
can be identiWed in peripheral blood, pDCs represent an
uncommon cell type that morphologically resembles
plasma cells [10]. During pro-inXammatory states, pDCs
are capable of generating type 1 interferons and migrating
to inXamed tissue sites (e.g. cutaneous SLE, contact derma-
titis, epidermis and dermis of psoriatic lesions) as well as
lymphoid tissues; type 1 interferon family members collec-
tively serve a wide variety of functions including antiviral
actions, the prevention of T-cell death, memory T-cell
expansion, stimulation of DC maturation, and activation of
NK cells [10, 15, 40, 48].
As in the bloodstream, distinct DC subsets have been
identiWed in the peripheral tissues: LCs are found in the epi-
dermis as well as in the stratiWed squamous epithelium of
vaginal and oral mucosa; CD11c+/CD11b+ submucosal
DCs are located beneath the mucosal epithelium; CD11b+
and CD11c+ dermal DCs are present under the skin base-
ment membrane [31, 69, 71, 73] (Table 1). LCs, which are
recognized as immature DCs, contain characteristic cyto-
plasmic Birbeck granules and express a variety of cell sur-
face molecules (e.g. Lag, Langerin, CD1a, CD205) [1, 18,
26,  29, 31]. Traditionally, LCs have been recognized as
major players in antigen capture, maturation, migration to
draining lymph nodes, and subsequent T-cell stimulation
through major histocompatibility complex (MHC) proteins.
[1,  3,  6,  16,  55,  56,  61]. As proposed by Zhao et al.
CD11c+/CD11b+ submucosal DCs, instead of LCs, may be
the dominant APCs when vaginal epithelium is infected by
certain pathogens such as herpes simplex virus (HSV) type
2; in this setting, submucosal DCs migrate to infected
regions, phagocytose viral antigen, travel to draining lymph
nodes, and present viral peptides to CD4+ T-cells thereby
stimulating T-cell activation and cytokine secretion [73].
Aside from anatomic localization, CD11b+ dermal DCs are
functionally similar to their submucosal counterparts [28].
Table 1 Cutaneous dendritic cell types and features of each subset
Type Features
CD14+ monocyte Comprise the majority of monocytes in humans [65]; give rise to tissue macrophages or myeloid DCs [54]
CD16+ monocyte Represent an infrequent monocyte population in humans [65]; give rise to DCs [65]
Plasmacytoid DC Under inXammatory conditions, enter lymph nodes via high endothelial venules and produce type 1 inter-
ferons [10]; increased numbers in psoriatic lesions [11]
Langerhans cell Contain characteristic intracellular Birbeck granules; immature DC of myeloid lineage [69]; can give rise 
to mature DC [69]; present in normal epidermis and psoriatic epidermis [31]
CD11c+/CD11b+ 
submucosal DC
Capable of antigen uptake, T-helper lymphocyte priming, and subsequent cytokine production in pro-
inXammatory states [73]
CD11b+ dermal DC Similar roles as CD11b+ submucosal DCs [28] 
CD11c+ dermal DC Immature DC of myeloid lineage [31]; when stimulated, become mature and capable of T-cell activation 
[69]; increased numbers in psoriatic skin [11]
CD11c+ iNOS- and 
TNF-producing cells
Similar to Tip-DCs, which are found in mice [35]; increased numbers in epidermis and dermis of psoriatic 
lesions [35]; express DC maturation markers CD83 and DC-LAMP [35]; decreased numbers following 
efalizumab treatment [35]
InXammatory epidermal DC  Epidermal counterpart to CD11c+ dermal DC; increased numbers in psoriatic epidermis [11]
Interferon-producing killer DC Possess properties of NK cells (e.g. NK-activating receptor expression; similar cytokine expression pro-
Wle); able to process/present antigen and activate T-cells; capable of producing type 1 IFN, type 2 IFN, 
or IL-12 depending on the activation stimulus [13]Arch Dermatol Res (2007) 299:359–366 361
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CD11c+ dermal DCs, which are recognized as immature
DCs, participate in immune surveillance within the dermis;
upon maturation, these cells are capable of T-cell activation
[31, 69]. As described by Lowes et al. a specialized type of
CD11c+ DC is signiWcantly increased in the epidermis and
dermis of psoriatic lesions in comparison to normal human
skin or uninvolved psoriatic skin; these cells (similar to
TNF- and iNOS-producing DC or “Tip DC” in mice)
express DC maturation markers (e.g. CD83) as well as the
enzyme inducible nitric oxide synthase (iNOS) and
increased levels of TNF- [35]. Classical models of DCs
suggest that tissue-resident DCs demonstrate two develop-
mental levels: an immature form functions in antigen cap-
ture; a mature form specializes in antigen presentation and
T-cell activation in peripheral lymphoid regions as well as
in peripheral tissues under pro-inXammatory conditions
(e.g. DCs and T-cells may interact within peripheral lym-
phoid-type areas of psoriatic skin, as described below) (a
discussion of DC subsets speciWc to peripheral lymphoid
tissues is beyond the scope of this review). As described in
the next section, DC–T-cell interactions depend upon MHC
proteins as well as co-stimulatory molecules; targeting this
latter mechanism has served as the cornerstone of biologic
agents in the treatment of psoriasis.
The recent identiWcation of interferon-producing killer
dendritic cells (IKDCs) illustrates the connection between
innate and adaptive immune processes; this DC subtype
also demonstrates the functional roles of both immature and
mature DCs [13]. As described by Chan et al. IKDCs share
features common to NK cells (e.g. NK-activating receptor
expression, similar cytokines produced) as well as activated
DCs. This DC subset is capable of antigen presentation and
processing, cytokine (i.e. type 1 and 2 IFN, IL-12) produc-
tion, T-cell activation, and possible anti-tumor actions [13].
Although initially described in mice, the human IKDC
counterpart has yet to be identiWed; characterization of this
versatile DC subtype in humans may hold key implications
in directing therapies against cancers and autoimmune dis-
eases such as psoriasis. Aside from anatomic location and
cell surface markers, DCs can be further classiWed based on
maturation status.
Immunologic roles of DCs
While present in the blood and peripheral tissues in an
immature form, DCs are thought to be mature following
stimulation and migration to secondary lymphoid tissues
[15]. The molecular changes demonstrated in the matura-
tion process correlate with the DC transition from cells pre-
dominantly involved in antigen detection and uptake to
professional APCs (Table 2). In contributing to this latter
role, DCs undergo a wide variety of modiWcations in
becoming mature: increased expression of costimulatory
molecules (CD40, CD80, CD86) and adhesion molecules
(VLA-4 and ICAM-1); the expression of CD83 and DC-
Lysosomal-Associated Membrane Protein (DC-LAMP),
which are markers of DC maturation; upregulation of
surface MHC molecules; decreased expression of pro-
inXammatory chemokine receptors and a corresponding
upregulation of lymphoid chemokine receptors (CCR7);
and downregulation of phagocytic and endocytic receptors
[6, 11, 15, 18, 51, 75]. DC maturation can be inXuenced by
a number of factors including DC interactions with compo-
nents of the innate immune system (TLR ligands, NK
cells), pro-inXammatory cytokine secretion, heat shock pro-
teins (HSPs), chemotaxins, chemokines, and costimulatory
molecule interactions; within the context of psoriatic
lesions, the speciWc antigen initiating the cascade of DC
maturation and downstream T-cell activation has yet to be
identiWed (Table 3).
The DC maturation process contributes to the eventual
activation of naïve T-cells along with the generation of
antigen-speciWc memory T-cells; this pathway begins with
Table 2 Immature versus mature dendritic cells: diVerences in surface markers and functional roles
Markers Functions
Immature Express CD1a [18, 26], lectin receptors [18], Toll-like receptors [28], 
natural killer (NK)-activating receptors (in the case of 
interferon-producing killer DCs) [13], pro-inXammatory 
chemokine receptors [15], intracellular MHC class II molecules [68]
Antigen capture via endocytosis, 
macropinocytosis, phagocytosis [18]; 
antigen processing [68]
Mature Co-stimulatory proteins (CD40, CD80, CD86) [44, 51], CD83 [33], 
DC-LAMP, increased surface MHC levels [18], upregulated cell 
adhesion molecules (e.g. intercellular adhesion molecule-1) [11] 
Lack of phagocytic function [18]; 
presence in secondary lymphoid 
tissues (DC migration is facilitated by 
the upregulation of lymphoid 
chemokine receptors) [15]; 
antigen presentation via MHC-peptide 
complexes [68]; binding and 
stimulating T-cells [43]; cytokine 
production and secretion [22]362 Arch Dermatol Res (2007) 299:359–366
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antigenic stimulation, which occurs through DC detection
and uptake of particles. DCs express distinct molecules that
may assist in traYcking to sites of inXammation: pro-
inXammatory chemokine receptors (CCR1, CCR5, and
CCR6); and receptors for platelet-activating factor (PAF)
and C5a, which represent chemotaxins often found at
inXammatory sites (e.g. psoriatic lesions) [18,  45,  63].
While proposed to be an important link between the innate
and adaptive immune systems in the generation of anti-
microbial responses, Toll-like receptors (TLRs) are
expressed by numerous cell types including DCs, neutroph-
ils, NK cells, mast cells, eosinophils, monocytes, mucosal
epithelial cells, macrophages, and keratinocytes [25,  28,
32]. Collectively, TLRs are able to detect a variety of viral
and bacterial components (e.g. unmethylated CpG DNA,
proteoglycans, and lipopolysaccharide) [28,  67]. Further
complicating the picture is that distinct DC subsets vary in
the TLRs that are expressed [28]. In light of their roles in
DC maturation, TLRs are recognized as key participants in
the generation of downstream T-cell responses. Within the
context of autoimmune disease, TLR-associated pathways
activate the transcription factor nuclear factor kappa B
(NF-B) with the eventual transcription of genes encoding
pro-inXammatory cytokines and proteins with microbicidal
eVects [39].
Following antigen recognition at peripheral sites, imma-
ture DCs perform antigen capture and processing through
mechanisms including receptor-mediated endocytosis,
phagocytosis, and macropinocytosis [18]. Once antigens
are captured and within the cell, processing occurs within
endosomes as the molecules are degraded into peptides that
are subsequently complexed with MHC class II molecules.
Immature DCs contain large numbers of intracellular MHC
class II rich compartments; as maturation takes place,
MHC–peptide complexes are exported to the cell mem-
brane for eventual antigen presentation to T-cells [68].
MHC class II presentation, while limited to macrophages,
DCs, and activated B- and T-cells, is also recognized as
exogenous (i.e. presented peptides originate from extracel-
lular proteins); this pathway helps present extracellular
pathogens [68]. On the other hand, MHC class I presenta-
tion involves all nucleated cells, protects against intracellu-
lar pathogens, and functions through an endogenous
pathway: intracellular proteins are degraded in the protea-
some and released into the cytosol; these cytosolic proteins
are transported to the endoplasmic reticulum, where they
are complexed with MHC class I molecules for subsequent
exportation to the cell surface [68]. MHC class I and II
molecules are utilized for presentation to CD8+ and CD4+
T-cells, respectively. MHC class I harbors the major psoria-
sis susceptibility locus PSORS1, which is present in
approximately 10% of psoriasis cases [23]. MHC class I
has also been associated with psoriasis susceptibility alleles
such as HLA-Cw  £ 0602, through which homozygotes
have a relative risk of 23.1 for developing disease and het-
erozygotes have a relative risk of 8.9; recent evidence indi-
cates that there is considerable overlap between HLA-Cw
alleles and the PSORS1 locus especially among patients
with early-onset psoriasis [2, 22, 46, 51].
Following antigen uptake and processing, DCs migrate
to secondary lymphoid tissues for presentation to T-cells.
DC traYcking to draining lymph nodes is orchestrated
through a complex interplay of pro-inXammatory cytokines
(TNF-, IL-1 beta, IL-18), chemokine and chemokine




(1) Microbial products (e.g. CpG motifs, lipopolysaccharide) stimulate pattern-recognition receptors (i.e. 
lectin receptors, Toll-like receptors) and subsequent antigen internalization [18, 28, 67]
(2) Antigen processing occurs through proteolysis by endocytic proteases, and results in the generation of 
peptides that are loaded on to MHC molecules [18]
DC migration (1) Pro-inXammatory chemokines, leukotrienes, cytokines, and other chemotaxins (e.g. C5a and PAF) 
facilitate DC migration to inXammatory sites [18, 45, 63] 
(2) Up-regulation of lymphoid chemokine receptors (CCR7) and down-regulation of pro-inXammatory 
chemokine receptors correlate with DC migration to secondary lymphoid tissues [15]
T-cell activation (1) DCs produce IL-12p70, which helps generate T-helper cell type 1 (Th1) responses [51]; IL-12p70 acts 
as a “third signal”, while enhancing CD8+ T-cell survival, clonal expansion, and eVector functions [17]; 
other possible stimulatory cytokines include IL-15, IL-18, IL-23, and IFN- [22, 36]
(2) Mature DCs exhibit surface MHC-peptide complexes for presentation to T-cells [18]
(3) Co-stimulatory signals (CD80 and CD86) and adhesion molecules (DC intercellular adhesion molecule-
1 binds to T-cell leukocyte-function-associated antigen-1) facilitate DC–T-cell interactions [52]
(4) Heat shock proteins and their corresponding receptors (CD91) stimulate: the upregulation of DC co-
stimulatory molecules; DC activation of T-cells; DC production of cytokines, which induce T-helper cell 
proliferation [8, 11]
(5) Cross-presentation and priming of cytotoxic T-lymphocytes [43]Arch Dermatol Res (2007) 299:359–366 363
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receptors (CCL19, CCR2, CCR6, CCR7), leukotrienes, and
cell adhesion molecules (e.g. E-cadherin down-regulation);
this process corresponds with a TLR-dependent down-
regulation of pro-inXammatory chemokine receptors and
up-regulation of lymphoid chemokine receptors [11, 15, 69,
72] (Table 3). Psoriatic lesions may serve as potential sites
for chronic T-cell activation through lymphoid-organizing
chemokines that are found at increased levels in psoriatic
lesions [33]. It has been proposed that these chemokines are
capable of organizing DCs and T-cells into lymphoid-type
tissues that can possibly support ongoing, peripheral APC–
T-cell interactions that are usually conWned to the lymph
nodes or spleen [33]. For example, psoriatic skin demon-
strates elevated expression of a ligand (CCL20/MIP-3
alpha) for the pro-inXammatory chemokine receptor CCR6;
as CCR6 is present on immature DCs as well as on memory
T-cells, it is thought that these cell types migrate to psori-
atic lesions while subsequently interacting and thereby gen-
erating downstream inXammatory-type responses [15, 24].
In arriving at the T-cell areas of lymphoid tissues,
mature DCs interact with T-cells in a number of ways.
These mechanisms include: antigen-speciWc interaction
through T-cell receptor association with the MHC–peptide
complex on the DC surface; costimulatory signals involv-
ing CD80 and CD86 which are expressed by mature DCs
and that are recognized by CD28 expressed on T-cells;
other costimulatory interactions (e.g. CD2:LFA-3, LFA-
1:ICAM-1) between T-cells and APCs; DC presentation of
non-peptide molecules (e.g. lipids) to T-cells through CD1-
mediated pathways; CD40–CD154 interactions; and cross-
presentation [26, 28, 43, 44, 49, 51]. Within the context of
psoriatic plaques, HSPs and their corresponding receptors
(i.e. CD91) inXuence DC activation of T-cells; certain
HSPs possess the ability to upregulate DC costimulatory
molecules, and also stimulate DC production of IL-12,
which triggers T-helper cell proliferation [8,  11]. DC
licensing by helper T-cells involves the expression of CD40
and CD154 by DCs and T-cells, respectively. As suggested
by Miga et al. CD40–CD154 associations are essential for
sustaining mature DC and T-cell populations, as well as
promoting T-cell proliferation following APC–T-cell inter-
actions [44]. In highlighting the importance of this system
in cell-mediated immunity, Smith et al. propose that DC
licensing is integral for generating and maintaining primary
and memory cytotoxic T-lymphocyte (CTL) responses
[62]. With regards to cell-mediated immunity, DCs also
possess the unique ability to cross-present antigens to
CD8+ CTLs. Through this mechanism, DCs present pro-
teins derived from the uptake and processing of extracellu-
lar antigens (e.g. tumor or virus-infected cells) and
subsequently stimulate CTLs; cross-presentation involves
pathogens that are unable to invade DCs and gain access to
endogenous MHC class I mechanisms [43]. In contrast to
cross-presentation, the involvement of self-antigens may
alternately lead to the attenuation of CTL responses (i.e.
tolerance) through distinct mechanisms: circulating T-lym-
phocytes may fail to recognize self-antigens; the removal of
self-reactive T-cells through apoptotic mechanisms;
impaired downstream responses following T-cell receptor
binding, such as in the absence of co-stimulatory interac-
tions [43]. Several factors (e.g. DC activation state, antigen
levels, duration of DC–T-cell interaction) determine
whether T-cell priming or tolerance occurs; for example,
immature DCs lack appropriate costimulatory signals and
lead to peripheral tolerance [43]. It has been suggested that
cross-presentation of certain foreign antigens (e.g. strepto-
coccal proteins), subsequent CD8+ T-cell priming, and
disturbances of regulatory mechanisms lead to potentially
self-perpetuating lesions present in chronic plaque psoriasis
[22].
DCs and psoriasis plaques
The interactions between DCs and T-cells, and associated
downstream responses play essential roles in the formation
of chronic psoriasis plaques. Recent studies have demon-
strated a high number of pDCs, immature as well as mature
DCs, CD11c+ iNOS-and TNF-producing cells, and inXam-
matory dendritic epidermal cells (i.e. the epidermal coun-
terpart to CD11c+ dermal DCs) within diseased skin [11,
35]. pDCs are also increased in uninvolved skin of individ-
uals with psoriasis, and may play a role in the subsequent
development of lesions [48]. With regards to functional
capabilities, dermal DCs within psoriatic lesions are stron-
ger stimulators of T-cell proliferation than are DCs derived
from peripheral blood or dermal DCs from the skin of
healthy patients [47]. It has been proposed that the prefer-
ential association between DCs and psoriatic epidermal
CD4+ T-cells may lead to the stimulation and subsequent
clonal expansion of epidermal CD8+ T-cells; along with
CD4+ T-cells and DCs, CD8+ T-cells are key players in the
production of pro-inXammatory cytokines that have been
implicated in psoriasis [22, 50, 53]. Along these lines, the
AGR129 mouse xenograft model has suggested that the
localized expansion of T-cells along with downstream cyto-
kine production play important roles in the development of
psoriatic plaques [7, 51]. Local skin-resident immune cells
(e.g. DCs, T-cells) and associated cytokines are present in
the uninvolved skin of psoriasis patients, and may be suY-
cient to initiate/maintain lesions following inciting triggers
[9].
An extensive cytokine network generated by activated
DCs and T-cells mediates the formation of psoriasis
lesions. Collectively, DCs have been shown to secrete
numerous cytokines that are implicated in psoriasis including364 Arch Dermatol Res (2007) 299:359–366
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TNF-, IFN-, IL-12, IL-23, and IL-15 [22, 36]. IFN-,
which is produced by pDCs that are present within psoriasis
plaques, plays a key role in the stimulation and prolifera-
tion of T-cells as well as the formation of psoriatic skin
[48]. IL-12 and IL-23 trigger T-helper cell activation and
associated downstream responses within the context of the
type 1 pathway in psoriasis [51]. As suggested by Zheng
et al. IL-23 activates T-helper cells that subsequently pro-
duce IL-17 and IL-22; this latter cytokine contributes to
dermal inXammation and epidermal hyperplasia character-
istic of psoriasis [74]. Similarly, IL-15 is a pro-inXamma-
tory cytokine that induces T-cell proliferation as well as
skin hyperplasia [11, 57, 70]. As noted previously in this
paper, activated T-cells secrete IFN- and TNF-, which
are essential players in the potentially self-perpetuating
type 1 pathway of psoriasis. In light of the immense cyto-
kine network described, there exist numerous possible tar-
gets for anti-psoriatic immunologic therapies.
DCs, T-cells, and anti-psoriatic immunotherapies
In targeting the mechanisms involving DCs, T-cells, and
cytokines within psoriatic lesions, immunologic therapies
have been successful in reducing disease severity. The
immunologic synapse (i.e. the platform for APC–T-cell
interactions) has been an eVective focus for therapy as sug-
gested by several key examples: psoralen and ultraviolet A
(PUVA) treatment resulted in decreased numbers of
lesional DCs as well as epidermal T-cells in association
with the clearing of chronic plaque psoriasis; cyclosporine
treatment applied to plaque psoriasis resulted in reduced
numbers of epidermal and dermal T-cells as well as
improvements in disease-related symptoms; alefacept (a
CD2-binding LFA-3 Ig fusion protein) has been proposed
to clear psoriasis lesions through the depletion of CD2-
expressing cells (e.g. lesional T-cells and DCs); efalizumab
(a human monoclonal antibody directed against LFA-1),
which blocks the interaction between leukocyte-function-
associated antigen-1 (LFA-1) on T-cells and intercellular
adhesion molecule-1 (ICAM-1) on DCs, is also eVective in
clearing psoriatic lesions as well as in reducing CD11c+ DC
numbers [4, 5, 12, 36, 52]. These Wndings suggest that the
mechanisms behind psoriasis depend upon interactions
between APCs and T-cells; blocking components of this
synapse could potentially minimize downstream responses
and disease severity. In addition to therapies targeting the
interactions between APCs and T-cells, emerging anti-pso-
riatic medications aim to modify cytokine responses in the
context of the type 1 pathway. TNF- antagonists such as
inXiximab and etanercept result in a rapid clearing of psori-
atic lesions [20,  41,  59]. Aside from their pro-apoptotic
roles, TNF- antagonists may act upon distinct inXamma-
tory pathways in psoriatic lesions; etanercept is associated
with decreases in pro-inXammatory cytokines and reduced
inWltration of cells characteristically involved in plaques
[21, 37, 38]. Another cytokine-focused treatment strategy
has involved the administration of IL-10 and other Th2
molecules (e.g. IL-4, IL-11) in an attempt to increase the
ratio of Th2:Th1 cytokines; this would presumably attenu-
ate the role of the type 1 pathway in psoriatic lesions [51].
IL-12, IL-15 and IL-23 also serve as promising targets for
anti-psoriatic therapies, as each of these cytokines has been
implicated in the type 1 pathway and in stimulating down-
stream cytokine production [31]. A phase 1 study evaluated
a humanized monoclonal antibody against the p40 subunit
of human IL-12; anti-IL-12p40 was well-tolerated and
eVectively cleared psoriatic lesions [30]. As additional
cytokines and costimulatory molecules are linked to the
pathogenesis of psoriatic lesions, immunologic therapies
will have an increased number of targets upon which to act.
Summary
In targeting DC–T-cell interactions and associated cytokine
networks, immunologic therapies have generally been
eVective in the treatment of psoriasis. As DCs are central
players in the potentially self-sustaining type 1 inXamma-
tory network, it is of great interest to further deWne DC
characteristics (e.g. DC life cycle, functional roles). DCs
also possess unique immunologic characteristics (e.g.
cross-presentation, linking innate and adaptive processes)
that can be exploited in the development of additional bio-
logic response therapies. The identiWcation of novel DC
subsets as well as further characterizing existing “players”
(e.g. IKDCs) will help achieve a greater understanding of
psoriasis and other chronic inXammatory conditions. DCs
serve a key role in the immunopathogenetic mechanisms
surrounding psoriasis and in the formation as well as suste-
nance of chronic plaques.
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